Author:
Roig J.,Sabria M.,Castella X.
Publisher
Springer Berlin Heidelberg
Reference94 articles.
1. Almirall J, Bolibar I, Toran P, Pera G, Boquet X, Balanzo X, et al. (2004) Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 125:1335–42
2. Alvarez-Sanchez B, Alvarez-Lerma F, Jordá R, Serra J, Lopez Cambra MJ, Sandar MD (1998) Prognostic factors and etiology in patients with severe community-acquired pneumonia. Study Group on Severe Community-Acquired Pneumonia in Spain. Med Clin (Barc) 111:650–4
3. Amsden GW (2005) Anti-inflammatory effects of macrolides — an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 55:10–21
4. Benhamou D, Bru JP, Chidiac C, Étienne J, Léophonte P, Marty N, et al. (2005) Legionnaires’ disease: definition, diagnosis and treatment. Med Mal Infect 35:1–5
5. Benin AL, Benson RF, Besser RE (2002) Trends in legionnaires’ disease, 1980–1998: declining mortality and new patterns of diagnosis. Clin Infect Dis 35:1039–46